This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Marksans Pharma Sep quarter 2026: half-year pre-tax profit up 91%, review clean
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.5 pts less than Nifty Microcap 250 and 5.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated unaudited results for the quarter and half year ended 30 Sep 2026 were approved on 4 Nov 2026 with an unmodified review; the quarter's income figures are not readable in this extract. Half-year consolidated: pre-tax profit Rs 4,000.74 mn versus Rs 2,099.32 mn a year earlier; operating cash flow Rs 3,215.16 mn versus Rs 751.86 mn. New units: QliniQ B.V. (EUR 7.50 mn) and ABCnow GmbH (EUR 1.10 mn).
Half-year profit and cash flow rose sharply and two European units were added, which may support the stock; borrowings are tiny.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹940.2 Cr | ₹720.4 Cr | +30.5% |
| Operating profit | ₹175.4 Cr | ₹111.8 Cr | +56.9% |
| Profit after tax | ₹143.5 Cr | ₹99.14 Cr | +44.8% |
| EBITDA margin | 22.8% | 20.1% | +2.7 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.